[1]李铭 郑冉 丛岩 秀芝 万全.心血管-肾脏-代谢综合征的最新研究进展[J].心血管病学进展,2025,(7):614.[doi:10.16806/j.cnki.issn.1004-3934.2024.07.008]
　LI Ming,ZHENG Ran,CONG Yan,et al.Recent Advances in Cardiovascular-Kidney-Metabolic Syndrome[J].Advances in Cardiovascular Diseases,2025,(7):614.[doi:10.16806/j.cnki.issn.1004-3934.2024.07.008]
点击复制

心血管-肾脏-代谢综合征的最新研究进展()

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2025年7期
页码:
614
栏目:
综述
出版日期:
2025-07-25

文章信息/Info

Title:
Recent Advances in Cardiovascular-Kidney-Metabolic Syndrome
作者:
李铭1 郑冉 1 丛岩 1 秀芝 万全2
(1.内蒙古民族大学临床医学院,内蒙古 通辽 028000;2.内蒙古民族大学附属医院心内科,内蒙古 通辽 028000)
Author(s):
LI Ming1; ZHENG Ran1; CONG Yan1; XIU Zhi1; WAN Quan2
(1.School of Clinical Medicine,Inner Mongolia Minzu University,Tongliao 028000,Inner Mongolia,China2. Department of Cardiovascular Medicine,Affiliated Hospital of Inner Mongolia Minzu University ,Tongliao 028000,Inner Mongolia,China)
关键词:
心血管-肾脏-代谢综合征; 2 型糖尿病; 心血管疾病; 慢性肾脏疾病
Keywords:
Cardiovascular-kidney-metabolic syndrome ;  Type 2 diabetes mellitus; Cardiovascular disease;  Chronic kidney disease
DOI:
10.16806/j.cnki.issn.1004-3934.2024.07.008
摘要:
心血管疾病、慢性肾脏疾病和2型糖尿病是与大量发病率和死亡率有关的三大疾病。最近，美国心脏协会将这种相互关联的健康状况的复杂网络统称为心血管-肾脏-代谢（CKM）综合征。解决CKM综合征预防、管理和治疗对于促进更好的患者健康结果至关重要。现对CKM综合征的最新研究进行全面总结。
Abstract:
Cardiovascular disease, chronic kidney disease, and type 2 diabetes are the top three diseases associated with a large number of morbidity and mortality. More recently,the American Heart Association has collectively referred to this complex network of interrelated health conditions as cardiovascular-renal-metabolic (CKM) syndrome. Addressing CKM syndrome prevention,management,and treatment is critical to promoting better patient health outcomes. This review is a comprehensive summary of the most recent research on CKM syndrome.

参考文献/References:

[1] Marassi M,Fadini GP. The cardio-renal-metabolic connection: a review of the evidence[J]. Cardiovasc Diabetol,2023,22(1):195.

[2] 国家心血管病中心,中国心血管健康与疾病报告编写组,胡盛寿. 中国心血管健康与疾病报告2023概要[J]. 中国循环杂志,2024,39(7):625-660.

[3] 国家卫生健康委员会. 中国卫生健康统计年鉴(2022)[M]. 北京:中国协和医科大学出版社,2022.

[4] 魏成,王梦龙,徐瑶,等. 1990～2019年中国人群2型糖尿病疾病负担及其危险因素分析[J]. 中国循证心血管医学杂志,2023,15(6):657-661.

[5] Ndumele CE,Rangaswami J,Chow SL,et al. Cardiovascular-kidney-metabolic health:a presidential advisory from the American Heart Association[J]. Circulation,2023,148(20):1606-1635.

[6] 凌鑫,林秀文,张莹,等. 2015-2021年我国城乡居民死亡状况分析[J]. 疾病监测,2024,39(3):369-375.

[7] Sun H,Saeedi P,Karuranga S,et al. IDF Diabetes Atlas:Global,regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J]. Diabetes Res Clin Pract,2022,183:109119.

[8] Arnold SV,Kosiborod M,Wang J,et al. Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry[J]. Diabetes Obes Metab,2018,20(8):2000-2003.

[9] Ndumele CE,Neeland IJ,Tuttle KR,et al. A Synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association[J]. Circulation,2023,148(20):1636-1664.

[10] Brownlee M. Biochemistry and molecular cell biology of diabetic complications[J]. Nature,2001,414(6865):813-820.

[11] Thomas MC,Brownlee M,Susztak K,et al. Diabetic kidney disease[J]. Nat Rev Dis Primers,2015,1:15018.

[12] Madonna R,de Caterina R. Cellular and molecular mechanisms of vascular injury in diabetes—Part I:Pathways of vascular disease in diabetes[J]. Vascul Pharmacol,2011,54(3-6):68-74.

[13] Whaley-Connell A,Sowers JR. Oxidative stress in the cardiorenal metabolic syndrome[J]. Curr Hypertens Rep,2012,14(4):360-365.

[14] Kadowaki T,Maegawa H,Watada H,et al. Interconnection between cardiovascular,renal and metabolic disorders:a narrative review with a focus on Japan[J]. Diabetes Obes Metab,2022,24(12):2283-2296.

[15] Ferdinand KC,Rodriguez F,Nasser SA,et al. Cardiorenal metabolic syndrome and cardiometabolic risks in minority populations[J]. Cardiorenal Med,2014,4(1):1-11.

[16] Kim H,Chung J,Kim K,et al. Lifestyle modification in the management of metabolic syndrome: statement from Korean Society of CardioMetabolic Syndrome (KSCMS)[J]. Korean Circ J,2022,52(2):93-109.

[17] Rao S,Pandey A,Garg S,et al. Effect of exercise and pharmacological interventions on visceral adiposity:a systematic review and meta-analysis of long-term randomized controlled trials[J]. Mayo Clin Proc,2019,94(2):211-224.

[18] Neeland IJ,Marso SP,Ayers CR,et al. Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk:a randomised,double-blind,placebo-controlled,clinical trial[J]. Lancet Diabetes Endocrinol,2021,9(9):595-605.

[19] Meyer-Gerspach AC,Peterli R,Moor M,et al. Quantification of liver,subcutaneous,and visceral adipose tissues by MRI Before and after bariatric surgery[J]. Obes Surg,2019,29(9):2795-2805.

[20] Barone Gibbs B,Hivert M,Jerome GJ,et al. Physical activity as a critical component of first-line treatment for elevated blood pressure or cholesterol: who,what,and how?: A scientific statement from the American Heart Association[J]. Hypertension,2021,78(2):e26-e37.

[21] Marso SP,Bain SC,Consoli A,et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes[J]. N Engl J Med,2016,375(19):1834-1844.

[22] Wiviott SD,Raz I,Bonaca MP,et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med,2019,380(4):347-357.

[23] Zelniker TA,Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review[J]. J Am Coll Cardiol,2020,75(4):422-434.

[24] Panico C,Bonora B,Camera A,et al. Pathophysiological basis of the cardiological benefits of SGLT-2 inhibitors:a narrative review[J]. Cardiovasc Diabetol,2023,22(1):164.

[25] Ussher JR,Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action[J]. Nat Rev Cardiol,2023,20(7):463-474.

[26] Dharia A,Khan A,Sridhar VS,et al. SGLT2 inhibitors: the sweet success for kidneys[J]. Annu Rev Med,2023,74:369-384.

[27] Beldhuis IE,Lam CSP,Testani JM,et al. Evidence-based medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease[J]. Circulation,2022,145(9):693-712.

[28] Forzano I,Wilson S,Lombardi A,et al. SGLT2 inhibitors: an evidence-based update on cardiovascular implications[J]. Expert Opin Investig Drugs,2023,32(9):839-847.

[29] Fisman EZ,Tenenbaum A. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect[J]. Cardiovasc Diabetol,2021,20(1):225.

[30] Nauck MA,D’Alessio DA. Tirzepatide,a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction[J]. Cardiovasc Diabetol,2022,21(1):169.

[31] Gonzalez-Juanatey JR,Gorriz JL,Ortiz A,et al. Cardiorenal benefits of finerenone: protecting kidney and heart[J]. Ann Med,2023,55(1):502-513.

[32] Pitt B,Filippatos G,Agarwal R,et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes[J]. N Engl J Med,2021,385(24):2252-2263.

[33] Blazek O,Bakris GL. Slowing the progression of diabetic kidney disease[J]. Cells,2023,12(15):1975.

[34] Ogunniyi MO,Commodore-Mensah Y,Ferdinand KC. Race,Ethnicity,Hypertension,and Heart Disease: JACC Focus Seminar 1/9[J]. J Am Coll Cardiol,2021,78(24):2460-2470.

[35] Kim B,Hong S,Lee Y,et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised,open-label,non-inferiority trial[J]. Lancet,2022,400(10349):380-390.

[36] Bhatt DL,Steg PG,Miller M,et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia[J]. N Engl J Med,2019,380(1):11-22.

[37] Powell-Wiley TM,Baumer Y,Baah FO,et al. Social determinants of cardiovascular disease[J]. Circ Res,2022,130(5):782-799.

[38] Karagiannis T,Bekiari E,Tsapas A. Socioeconomic aspects of incretin-based therapy[J]. Diabetologia,2023,66(10):1859-1868.

[39] Claudel SE,Verma A. Cardiovascular-kidney-metabolic syndrome: a step toward multidisciplinary and inclusive care[J]. Cell Metab,2023,35(12):2104-2106.

相似文献/References:

[1]殷钰喆 李喆 吴永健.心血管-肾脏-代谢综合征视角下动脉粥样硬化性心血管疾病的现状与管理策略[J].心血管病学进展,2025,(4):289.[doi:10.16806/j.cnki.issn.1004-3934.2024.04.001]
　YIN Yuzhe,LI Zhe,WU Yongjian.Current Status and Management Strategies of Atherosclerotic Cardiovascular Disease from The Perspective of Cardio-Renal-Metabolic Syndrome[J].Advances in Cardiovascular Diseases,2025,(7):289.[doi:10.16806/j.cnki.issn.1004-3934.2024.04.001]
[2]王世鹏 付秋玉 刘剑雄 胡咏梅.非奈利酮临床应用研究进展[J].心血管病学进展,2025,(10):879.[doi:10.16806/j.cnki.issn.1004-3934.2025.10.004]
　WANG Shipeng,FU Qiuyu,LIU Jianxiong,et al.Clinical Application of Finerenone[J].Advances in Cardiovascular Diseases,2025,(7):879.[doi:10.16806/j.cnki.issn.1004-3934.2025.10.004]
[3]白慧茹 庞建中.心血管-肾脏-代谢综合征的提出与临床现状[J].心血管病学进展,2025,(12):1071.[doi:10.16806/j.cnki.issn.1004-3934.2025.12.004]
　BAI Huiru,PANG Jianzhong.Proposal and Clinical Status of Cardiovascular-Kidney-Metabolic Syndrome[J].Advances in Cardiovascular Diseases,2025,(7):1071.[doi:10.16806/j.cnki.issn.1004-3934.2025.12.004]

更新日期/Last Update: 2025-09-30